Published in J Clin Oncol on June 01, 2007
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res (2010) 3.35
Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev (2008) 1.83
Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia (2011) 1.78
Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res (2012) 1.55
Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med (2008) 1.54
Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res (2011) 1.46
Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer (2010) 1.37
Chemotherapy-related posterior reversible leukoencephalopathy syndrome. Nat Clin Pract Neurol (2009) 1.21
Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier. MAbs (2011) 1.20
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med (2013) 1.19
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer (2014) 1.14
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol (2014) 1.09
The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.04
Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol Ther (2009) 1.03
Emerging strategies for treating brain metastases from breast cancer. Cancer Cell (2015) 1.00
New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat Clin Pract Oncol (2008) 0.99
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. Br J Cancer (2011) 0.98
Fluorescent affibody peptide penetration in glioma margin is superior to full antibody. PLoS One (2013) 0.94
The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Int J Clin Oncol (2009) 0.93
Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res (2016) 0.92
Pazopanib inhibits the activation of PDGFRβ-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells. Am J Pathol (2013) 0.91
MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas. J Cereb Blood Flow Metab (2009) 0.90
Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial. Onco Targets Ther (2012) 0.89
Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. PLoS One (2013) 0.89
Engineered knottin peptide enables noninvasive optical imaging of intracranial medulloblastoma. Proc Natl Acad Sci U S A (2013) 0.86
The management of brain metastases in non-small cell lung cancer. Front Oncol (2014) 0.85
Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib. World J Surg Oncol (2012) 0.85
Effect of chemotherapy on survival after whole brain radiation therapy for brain metastases: a single-center retrospective analysis. J Cancer Res Clin Oncol (2012) 0.84
Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist (2015) 0.84
Multimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases. J Control Release (2013) 0.83
Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer. Clin Exp Metastasis (2016) 0.83
TP53 regulates human AlkB homologue 2 expression in glioma resistance to Photofrin-mediated photodynamic therapy. Br J Cancer (2010) 0.83
DNA topoisomerase I drugs and radiotherapy for lung cancer. J Thorac Dis (2012) 0.83
Regression of brain metastases from breast cancer with eribulin: a case report. BMC Res Notes (2013) 0.82
Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res (2016) 0.81
Quantitative Fluorescent Microscopy to Measure Vascular Pore Sizes in Primary and Metastatic Brain Tumors. Cancer Res (2016) 0.80
Small vessel ischemic disease of the brain and brain metastases in lung cancer patients. PLoS One (2009) 0.79
Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report. BMC Cancer (2015) 0.78
Attributes of brain metastases from breast and lung cancer. Int J Clin Oncol (2012) 0.78
Gliadel for brain metastasis. Surg Neurol Int (2013) 0.77
Novel treatment strategies for brain tumors and metastases. Pharm Pat Anal (2014) 0.77
Fluoxetine modulates breast cancer metastasis to the brain in a murine model. BMC Cancer (2014) 0.77
Short-time focused ultrasound hyperthermia enhances liposomal doxorubicin delivery and antitumor efficacy for brain metastasis of breast cancer. Int J Nanomedicine (2014) 0.77
Lapatinib for the treatment of breast cancer in the People's Republic of China. Onco Targets Ther (2014) 0.76
Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions. Expert Opin Drug Metab Toxicol (2009) 0.76
Crossing the barrier: treatment of brain tumors using nanochain particles. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.76
Challenges in the delivery of therapies to melanoma brain metastases. Curr Pharmacol Rep (2016) 0.75
Intercellular transfer of small RNAs from astrocytes to lung tumor cells induces resistance to chemotherapy. Oncotarget (2016) 0.75
Efficacy of XELOX plus Bevacizumab in Brain Metastasis from Rectal Cancer. Case Rep Oncol (2014) 0.75
Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases. J Thorac Dis (2016) 0.75
Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 and their affinities for the large neutral amino acid transporter (system LAT1) of the blood-brain barrier. Bioorg Med Chem Lett (2010) 0.75
Early gastric cancer with suspected brain metastasis arising eight years after curative resection: a case report. BMC Res Notes (2014) 0.75
Safety and efficacy of carmustine (BCNU) wafers for metastatic brain tumors. Surg Neurol Int (2016) 0.75
In silico prediction of inhibition of promiscuous breast cancer resistance protein (BCRP/ABCG2). PLoS One (2014) 0.75
Cancer and the metastatic substrate. Ecancermedicalscience (2016) 0.75
Inhibition of VEGF and Angiopoietin-2 to Reduce Brain Metastases of Breast Cancer Burden. Front Pharmacol (2017) 0.75
Melanoma Brain Metastases: Current Areas of Investigation and Future Directions. Cancer J (2017) 0.75
Embracing rejection: Immunologic trends in brain metastasis. Oncoimmunology (2016) 0.75
Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options. Cell Oncol (Dordr) (2017) 0.75
Drug Delivery to Melanoma Brain Metastases: Can Current Challenges Lead to New Opportunities? Pharmacol Res (2017) 0.75
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer (2010) 2.74
Pancreatic cancer and thromboembolic disease. Lancet Oncol (2004) 2.10
Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res (2010) 1.92
Language matters: "sometimes we withdraw treatment but we never withdraw care". J Palliat Med (2007) 1.45
Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer. J Clin Oncol (2009) 1.24
Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery (2011) 1.14
Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer (2008) 1.13
Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. Oncogene (2003) 1.06
Selective depletion of mutant p53 by cancer chemopreventive isothiocyanates and their structure-activity relationships. J Med Chem (2011) 1.03
Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143. Cancer Res (2003) 1.00
Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor. Pituitary (2011) 0.98
A novel stereo-selective sulfonylurea, 1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one, has antitumor efficacy in in vitro and in vivo tumor models. Biochem Pharmacol (2002) 0.92
Head and neck squamous cell carcinoma in FAMMM syndrome. Head Neck (2009) 0.91
Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomas. Proc Natl Acad Sci U S A (2007) 0.91
Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival. J Gastrointest Surg (2007) 0.91
NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells. Biochemistry (2004) 0.90
Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway. Mol Cancer Ther (2005) 0.89
Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas. Pancreas (2008) 0.89
Transient cerebral hypoperfusion enhances intraarterial carmustine deposition into brain tissue. J Neurooncol (2007) 0.89
The intensity and frequency of moral distress among different healthcare disciplines. J Clin Ethics (2013) 0.89
Cost savings from palliative care teams and guidance for a financially viable palliative care program. Health Serv Res (2014) 0.88
Restoration of p53 function for selective Fas-mediated apoptosis in human and rat glioma cells in vitro and in vivo by a p53 COOH-terminal peptide. Mol Cancer Ther (2006) 0.86
PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer (2006) 0.85
Correlation between hydrophobic properties and efficiency of carrier-mediated membrane transduction and apoptosis of a p53 C-terminal peptide. Biochem Biophys Res Commun (2002) 0.85
Activation of targeted necrosis by a p53 peptide: a novel death pathway that circumvents apoptotic resistance. J Biol Chem (2007) 0.85
Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients. J Neurooncol (2006) 0.84
High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery (2014) 0.84
The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells. Clin Cancer Res (2002) 0.84
Selective induction of apoptosis through the FADD/caspase-8 pathway by a p53 c-terminal peptide in human pre-malignant and malignant cells. Int J Cancer (2005) 0.83
Intra-arterial mitoxantrone delivery in rabbits: an optical pharmacokinetic study. Neurosurgery (2011) 0.83
The use of fluorescent probes in the study of reactive oxygen species in pancreatic cancer cells. Methods Mol Biol (2013) 0.80
Treatment preferences of seriously ill patients. N Engl J Med (2002) 0.80
The role of alpha-helical structure in p53 peptides as a determinant for their mechanism of cell death: necrosis versus apoptosis. Adv Drug Deliv Rev (2005) 0.80
The feasibility of real-time in vivo optical detection of blood-brain barrier disruption with indocyanine green. J Neurooncol (2011) 0.79
Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDAC. Mol Cancer Ther (2013) 0.79
The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX. Surg Oncol Clin N Am (2004) 0.79
Stereotactic radiosurgery plays a critical role in enhancing long-term survival in a patient with pancreatic cancer metastatic to the brain. Anticancer Res (2013) 0.78
Computational protein chemistry of p53 and p53 peptides. Front Biosci (2004) 0.77
Significant reduction of laparotomy-associated lung metastases and subcutaneous tumors after perioperative immunomodulation with flt3 ligand in mice. Surg Innov (2005) 0.77
Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature. Oncology (2012) 0.77
Perioperative immunomodulation with Flt3 kinase ligand or a whole tumor cell vaccine is associated with a reduction in lung metastasis formation after laparotomy in mice. Surg Innov (2006) 0.76
Tackling medical futility in Texas. N Engl J Med (2007) 0.75
Panniculitis after vaccination against CEA and MUC1 in a patient with pancreatic cancer. Lancet Oncol (2005) 0.75
Acute ascending aortic dissection diagnosed with transthoracic echocardiography. J Am Soc Echocardiogr (2009) 0.75
Is it always wrong to perform futile CPR? N Engl J Med (2010) 0.75
BRD-glucan exhibits potent immunochemotherapeutic activity in vitro and in vivo. Int J Oncol (2005) 0.75